Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|24|1|104-112

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.24, Iss.1, 2018-01, pp. : 104-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

By  

HAEMOPHILIA, Vol. 21, Iss. 2, 2015-03 ,pp. : 196-203

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

By  

HAEMOPHILIA, Vol. 21, Iss. 5, 2015-09 ,pp. : e436-e439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : e436-e439

John Wiley & Sons Inc

Access to resources Recommend Favorite

The pharmacokinetics of a B‐domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 370-379

John Wiley & Sons Inc

Access to resources Recommend Favorite